



## Entasis Therapeutics to Present Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

April 21, 2017

**WALTHAM, Mass. — April 21, 2017—**[Entasis Therapeutics](#), a leader in the discovery and development of breakthrough anti-infective products, today announced two oral presentations at the 27<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases ([ECCMID](#)), which is being held April 22 – 25 in Vienna, Austria. Both presentations will highlight the preclinical profile of ETX2514, Entasis' next-generation beta-lactamase inhibitor with an expanded spectrum of activity against Class A, C, and D beta-lactamases, as well as that of ETX2514SUL, the combination of ETX2514 with sulbactam which is being developed for the treatment of *A. baumannii* infections. ETX2514SUL is currently in Phase 1 clinical trials.

Details of the presentations are as follows:

**Title:** ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens

**Date and Time:** Monday April 24, 9:00 AM

**Location:** Hall K

**Abstract #:** 4097

**Presenter:** Dr. Ruben Tommasi

**Title:** Restoration of sulbactam activity against multidrug resistant *Acinetobacter baumannii* by the novel, broad spectrum  $\beta$ -lactamase inhibitor ETX2514 correlates with  $\beta$ -lactamase inhibition in vitro and in vivo

**Date and Time:** Monday April 24, 9:36 AM

**Location:** Hall K

**Abstract #:** 5942

**Presenter:** Dr. Alita Miller

### About ETX2514

ETX2514 is a potent and broad spectrum inhibitor of class A, C, and D beta-lactamases. ETX2514 restores the *in vitro* activity of multiple beta-lactams against Gram-negative, multi-drug resistant (MDR) pathogens. Entasis Therapeutics is developing ETX2514SUL, the combination of ETX2514 and sulbactam, for the treatment of severe *A. baumannii* infections. *A. baumannii* is a Gram-negative bacterium that causes severe infections which are associated with high mortality rates. *A. baumannii* infections are frequently multi-drug resistant and there is an urgent need to identify new safe and effective agents to treat affected patients. Sulbactam is a generic beta-lactam which has intrinsic activity against *A. baumannii* but suffers from widespread beta-lactamase-mediated resistance. In preclinical studies, ETX2514 restores sulbactam's antimicrobial activity against *A. baumannii*. ETX2514SUL is currently in Phase 1 clinical trials.

### About Entasis Therapeutics Inc.

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis' anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting infections caused by *Acinetobacter baumannii* infections) and zoliflodacin (targeting the treatment of *Neisseria gonorrhoeae* infections) currently in the clinic. [www.entasistx.com](http://www.entasistx.com)

### Company Contact

Kyle Dow

Entasis Therapeutics

(781) 810-0114

[kyle.dow@entasistx.com](mailto:kyle.dow@entasistx.com)

### Media Contact

Kari Watson

MacDougall Biomedical Communications (781) 235-3060

[kwatson@macbiocom.com](mailto:kwatson@macbiocom.com)